GSK's depemokimab accepted for review by Health Canada for the treatment of asthma with type 2 inflammation and for chronic rhinosinusitis with nasal polyps
SWIFT-1 and -2 trials showed depemokimab reduced exacerbation and hospitalization rates as an add-on therapy for patients with asthma with type 2 inflammation versus placebo
ANCHOR-1 and -2 trials showed early and sustained reductions in nasal polyp size and nasal obstruction versus placebo for patients with chronic rhinosinusitis with nasal polyps
Across the SWIFT and ANCHOR clinical trials, the overall incidence and severity of treatment-emergent adverse events were similar in patients treated with either depemokimab or placebo
If approved, depemokimab will be the first ultra-long-acting biologic with two doses per year (6-month dosing)
MISSISSAUGA, ON, May 26, 2025 /CNW/ - GSK has submitted a New Drug Submission (NDS) to Health Canada for depemokimab for two proposed indications: The first indication is as an add-on maintenance treatment of asthma in adult and adolescent patients aged 12 years and older with type 2 inflammation characterized by an eosinophilic phenotype on medium- to high-dose inhaled corticosteroids (ICS) plus another asthma controller. The second indication is as an add-on maintenance treatment of adult patients with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP). The NDS is based on data from the positive SWIFT and ANCHOR trials.
Michelle Horn, Country Medical Director, GSK Canada, said: "The combined submission for asthma and CRSwNP marks a significant step toward addressing the unmet needs of patients. Backed by strong clinical evidence, depemokimab has the potential to become the first ultra-long-acting biologic offering patients sustained inhibition of IL-5, a key driver of their disease with twice-yearly dosing, and represents a promising advancement for patients and physicians alike."
Depemokimab, a monoclonal antibody that targets IL-5, is the first ultra-long-acting biologic to be evaluated in phase III trials. 1, 2, 3 IL-5 is a key cytokine (protein) in type 2 inflammation. 1, 5, 6 Type 2 inflammation is typically identified by blood eosinophil count and is an underlying driver in many diseases. This type of inflammation is present in the majority of patients with difficult to treat asthma and can lead to exacerbations and hospitalization. 5, 6, 7 Type 2 inflammation is also present in up to 85% of people with CRSwNP and is associated with more severe disease and symptoms. 8, 9, 10, 11, 12 With IL-5 inhibition, eosinophils are significantly reduced and there is evidence to show IL-5 has broader effects on other structural and immune cell types beyond eosinophils. 5, 6, 22, 23, 24, 25, 26
In patients with asthma with type 2 inflammation and patients with CRSwNP, the SWIFT and ANCHOR trials, respectively, met their primary endpoints, showing that depemokimab could offer sustained inhibition of an important driver of their disease, and help achieve key clinical outcomes with a dosing schedule of just two injections per year. 1, 2, 3 Depemokimab's extended half-life, high-binding affinity and potency, support a dosing regimen of one injection every six months (26 weeks).. 1, 2, 3 As demonstrated in studies of other diseases, longer intervals between doses have been shown to overcome barriers to optimal care, such as patient adherence, and can reduce the burden of disease for patients. 4
In Canada, more than 4.7 million people are currently affected by asthma, a chronic and sometimes debilitating condition. 27 Many Canadian asthmatics continue to experience symptoms such as difficulty breathing and chest tightness, despite treatment with high-dose inhaled corticosteroids plus a second controller (and/or systemic corticosteroids). 5,20
People with CRSwNP experience symptoms such as nasal obstruction, loss of smell, facial pain, sleep disturbance, infections and nasal discharge that can significantly affect their emotional and physical well-being. 8, 9, 10, 11 Such symptoms mean the impact of CRSwNP on overall quality of life has been reported to be comparable with other chronic diseases such as COPD, asthma, and diabetes. 9
The safety and effectiveness of depemokimab are still under investigation and authorization has not yet been granted. Depemokimab is currently not approved for use in any country.
About SWIFT-1 and SWIFT-2
SWIFT-1 and SWIFT-2 were replicate 52-week, randomised (2:1), double-blind, placebo-controlled, parallel-group, multi-centre Phase III clinical trials. 1 The trials assessed the efficacy and safety of depemokimab as adjunctive therapy in 382 and 380 participants with severe asthma with type 2 inflammation characterised by blood eosinophil count, including adult and adolescent patients, who were randomised to receive depemokimab or a placebo respectively, in addition to their standard of care treatment with medium to high-dose inhaled corticosteroids plus at least one additional controller. 1 In each trial, the rate of asthma exacerbations was significantly lower in the depemokimab group than in the placebo group. 1
These results have been reported and published in the New England Journal of Medicin e. 1
About ANCHOR-1 and ANCHOR-2
ANCHOR-1 and ANCHOR-2 were replicate 52-week, randomised (1:1), double-blind, placebo-controlled, parallel-group, multi-centre Phase III clinical trials. 2, 3 The trials assessed the efficacy and safety of depemokimab as add-on therapy to standard of care in 271 and 257 adult patients with CRSwNP inadequately controlled on intranasal corticosteroids. 2, 3 The co-primary endpoints were met with statistically significant reductions in nasal polyp size and nasal obstruction in patients receiving depemokimab versus placebo, at 52 weeks. 2, 3
Full results of ANCHOR-1 and ANCHOR-2 have been reported and published in The Lancet. 19
About GSK in respiratory
GSK is redefining the future of respiratory medicine as it builds on decades of pioneering work to deliver more ambitious treatment goals and develop the next-generation standard of care, for hundreds of millions of people with respiratory diseases. With an industry-leading respiratory portfolio and pipeline of vaccines, targeted biologics, and inhaled medicines, we are focused on improving outcomes and the lives of people living with all types of asthma and COPD along with less understood diseases like refractory chronic cough or rarer conditions like systemic sclerosis with interstitial lung disease. GSK is harnessing the latest science and technology with the aim to modify underlying disease dysfunction and prevent disease progression.
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.ca.gsk.com/en-ca.
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2024, and GSK's Q1 Results for 2025.
1.
Jackson DJ, et al. Six Monthly Depemokimab in Severe Asthma With an Eosinophilic Phenotype. NEJM. Published on September 9 at NEJM.org.
2.
ClinicalTrials.gov. Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps (ANCHOR-1) Available at: https://clinicaltrials.gov/study/NCT05274750. Accessed February 2025
3.
ClinicalTrials.gov. Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps (ANCHOR-2) Available at: https://clinicaltrials.gov/study/NCT05281523. Accessed February 2025
4.
Scarsi KK, Swindells S. The Promise of Improved Adherence With Long-Acting Antiretroviral Therapy: What Are the Data? Journal of the International Association of Providers of AIDS Care (JIAPAC). 2021;20.
5.
Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention,2024. Updated May 2024. Available at: https://ginasthma.org/. Accessed February 2025.
6.
Heaney L, et al. Eosinophilic and Noneosinophilic Asthma: An Expert Consensus Framework to Characterize Phenotypes in a Global Real-Life Severe Asthma Cohort. Chest. 2021;160(3):814-830.
7.
Principe S, et al. Severe asthma: Targeting the IL-5 pathway. Clin Exp Allergy. 2021 Aug;51(8):992-1005
8.
Laidlaw TM, et al. Chronic Rhinosinusitis with Nasal Polyps and Asthma. J. Allergy Clin. Immunol. 2001;9(3):1133-1141.
9.
Bachert C, et al. Burden of Disease in Chronic Rhinosinusitis with Nasal Polyps. J Asthma Allergy. 2021;b 11;14:127-134.
10.
De Corso E, et al. How to manage recurrences after surgery in CRSwNP patients in the biologic era: a narrative review. Acta Otorhinolaryngol Ital. 2023;43(Suppl. 1):S3-S13.
11.
Chen S, et al. Systematic literature review of the epidemiology and clinical burden of chronic rhinosinusitis with nasal polyposis. Curr Med Res Opin. 2020;36(11):1897-1911.
12.
Bachert C, et al. EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: Definitions and management. J Allergy Clin Immunol. 2021;147(1):29-36.
13.
American Lung Association. Severe Asthma. Available at: https://www.lung.org/lung-health-diseases/lung-disease-lookup/asthma/learn-about-asthma/types/severe-asthma. Accessed February 2025.
14.
American Lung Association. Asthma Trends and Burden. Available at: https://www.lung.org/research/trends-in-lung-disease/asthma-trends-brief/trends-and-burden. Accessed February 2025.
15.
ClinicalTrials.gov. An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103) (AGILE). Available at: https://clinicaltrials.gov/study/NCT05243680. Accessed February 2025.
16.
ClinicalTrials.gov. A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype (NIMBLE). Available at: https://clinicaltrials.gov/study/NCT04718389. Accessed February 2025.
17.
ClinicalTrials.gov. Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) Available at: https://clinicaltrials.gov/study/NCT05263934. Accessed February 2025.
18.
ClinicalTrials.gov. Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial (DESTINY) Available at: https://clinicaltrials.gov/study/NCT05334368. Accessed February 2025.
19.
Gevaert P, et al. Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): phase III, randomised, double-blind, parallel trials. The Lancet. Published on February 28 at thelancet.com.
20.
World Health Organisation. Asthma Key Facts. Available at: https://www.who.int/news-room/fact-sheets/detail/asthma. Accessed February 2025
21.
Israel, E, et al. Severe and Difficult-to-Treat Asthma in Adults. N Engl J Med 2017;377:965-76.
22.
Buchheit KM, et al. Mepolizumab targets multiple immune cells in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2021;148(2):574-584.
23.
Barretto KT, et al. Human airway epithelial cells express a functional IL-5 receptor. Allergy. 2020;75(8):2127-2130.
24.
Bajbouj K, et al. IL-5 receptor expression in lung fibroblasts: Potential role in airway remodelling in asthma. Allergy. 2023;78(3):882-885.
25.
Siddiqui S, et al. Eosinophils and tissue remodeling: Relevance to airway disease. J Allergy Clin Immunol. 2023;152(4):841-857.
26.
Bergantini L, et al. Regulatory T cell monitoring in severe eosinophilic asthma patients treated with mepolizumab. Scand J Immunol. 2021;94(1):e13031.
SOURCE GlaxoSmithKline Inc.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
19 hours ago
- Cision Canada
World-first clinical trial confirms exercise improves survival for colon cancer Français
A Canadian Cancer Society-funded trial reveals that guided exercise can save and prolong lives by reducing risk of cancer recurrence and second cancers TORONTO, June 1, 2025 /CNW/ - A groundbreaking clinical trial funded by the Canadian Cancer Society (CCS) shows that physical activity can significantly improve outcomes for people with colon cancer. Researchers say the study is the first in the world to use structured exercise to increase cancer survival. The trial results, presented today at the American Society of Clinical Oncology annual conference and published in the New England Journal of Medicine, have the potential to change clinical practice. They show that, when incorporated into cancer care for people with colon cancer, a structured exercise program reduces the risk of cancer recurrence and of new primary cancers developing. "Our findings show that exercise is no longer just a quality-of-life intervention for cancer patients that can be offered when and where possible," says study co-chair Dr Kerry Courneya, a professor of kinesiology at the University of Alberta and Canada Research Chair in Physical Activity and Cancer. "It is a treatment for colon cancer that must be made available to all patients." Colorectal cancer is the second leading cause of cancer death in Canada. Last year, an estimated 25,200 Canadians were diagnosed with colorectal cancer and 9,400 people died from it. To improve outcomes, a team led by Dr Courneya and Dr Chris Booth – study co-chair, medical oncologist at Kingston Health Sciences Centre and professor of oncology at Queen's University – has been working with the Canadian Cancer Trials Group (CCTG) on this first-of-its kind trial. The 17-year international trial involved 889 people, all of whom had been diagnosed with and treated for colon cancer. After having surgery and chemotherapy, participants were given a 3-year structured exercise program or standard health education materials that are currently given to patients. Each participant in the exercise program chose their own forms of moderate-intensity exercise – from walking to pickleball – with the goal of adding 2.5 hours of exercise per week to their regular activity schedule. The outcome: those who received the exercise program had a 28% lower risk of recurrence and new cancers and a 37% lower risk of death. "This is the first clinical trial in the world designed to answer whether exercise can improve cancer survival, and the results are clear," says Dr Booth. "The next step is to put this into practice. That means health systems will need to invest in behaviour support programs as part of standard care." The researchers are currently conducting a comprehensive health economic analysis. According to Dr Booth, they anticipate that the program will be "remarkably cost-effective compared to many new cancer drugs," making it sustainable for health systems. Terri's story Terri Swain-Collins was diagnosed with stage 3 colon cancer in 2021 after a screening test led to further investigation. Following treatment including surgery and chemotherapy, she was invited to join Dr Booth and Dr Courneya's clinical trial. During the trial, she worked closely with a physiotherapist to establish and maintain a fitness routine personalized to her needs. "One of the biggest benefits was having a semi-structured routine that works for my lifestyle with someone to hold me accountable," says Terri. "Simply being told to exercise by a physician wouldn't have been enough to get me to where I am today; having someone walk alongside me, guide me and check in regularly was what truly made it possible." Now, 3 years later, Terri continues to walk 3 times a week, feels fit and remains cancer-free. She says she is grateful for the impact of the program on her health and well-being. "By bridging the gap between bold ideas and routine practice, clinical trials are essential to driving research progress that can benefit patients," says Dr Stuart Edmonds, Executive Vice President, Mission, Research and Advocacy at CCS. "The results of this trial have the potential to save and improve lives for the tens of thousands of people in Canada affected by colorectal cancer each year, and we are proud our donors enabled us to support it." The international study co-chair was Dr Janette Vardy, from The University of Sydney (Australia) with funding from National Health and Medical Research Council. The UK team was led by Dr Victoria Coyle at Queen's University of Belfast, supported by Cancer Research UK. About the Canadian Cancer Society The Canadian Cancer Society works tirelessly to save and improve lives. We raise funds to fuel the brightest minds in cancer research. We provide a compassionate support system for all those affected by cancer, across Canada and for all types of cancer. Together with patients, supporters, donors and volunteers, we work to create a healthier future for everyone. Because to take on cancer, it takes all of us. It takes a society. Help us make a difference. Call 1-888-939-3333 or visit today. About the Canadian Cancer Trials Group The Canadian Cancer Trials Group (CCTG) is a cancer clinical trials research cooperative that runs phase I–III trials to test anti-cancer and supportive therapies at over 85 hospitals and cancer centres across Canada. From their operations centre at Queen's University, CCTG has supported more than 600 trials enrolling 100,000 patients from 40 countries on 6 continents through a global network of 20,000 investigators and clinical trial staff. CCTG is the Canadian Coordinating Clinical Trial Network for the US NCTN and is a national program of the Canadian Cancer Society. CCTG's aim is to improve survival and quality of life for all people with cancer. Learn more at
Cision Canada
20 hours ago
- Cision Canada
/R E P E A T -- MEDIA ADVISORY - Walking in Support of the 322,000+ people in Canada with Crohn's or colitis/ USA
Every 48 minutes – another Canadian is diagnosed with Crohn's or colitis; by 2035, 470,000+ Canadians will be living with IBD TORONTO, May 30, 2025 /CNW/ - WHAT: On Sunday, June 1, 2025, Crohn's and Colitis Canada, along with Canada's Inflammatory Bowel Disease (IBD) community, will participate in Gutsy Walk, a national fundraising event that supports the 322,000+ people living with Crohn's or colitis. Gutsy Walk, Crohn's and Colitis Canada's largest fundraising initiative, raises funds that go directly towards national research, advocacy, and patient programs. WHO: Those living with Crohn's or colitis, community members, friends, family and local representatives. WHEN: Sunday, June 1, 2025. Event start times may vary by location. WHERE: 30+ locations nationwide – from coast to coast. To register a team, donate and view locations, visit: WHY: There is no cure for Crohn's or colitis. Treatment focuses on achieving and maintaining remission, minimizing complications, preventing lasting intestinal damage, and improving quality of life. Crohn's and colitis are lonely diseases, with stigma and isolation added onto physical symptoms. SPOKESPERSON QUOTES: Jayda Sutton of Oakville, ON: Longstanding participant who lives with colitis and is the Ontario Provincial Honourary Chair. "I walk to honour my journey, my son Grayson who passed away at eight months gestation due to complications related to my colitis, my daughter Alyssa, my husband Chris, my parents and everyone who has stood with me. I want to use my story to highlight the quiet victories – getting back up when you feel defeated." Kate Lee, VP, Research & Patient Programs, Crohn's and Colitis Canada:"Gutsy Walk is a celebration of resilience. These are isolating diseases, which makes Gutsy Walk an important moment for those affected to come together and contribute to a better future for themselves." We are on a relentless journey to cure Crohn's and colitis and improve the quality of life of everyone affected by these diseases. Get the latest Gutsy Walk information on Instagram and Facebook - @gutsywalk and @getgutyscanada, as well as For information on Crohn's and Colitis Canada, visit
Cision Canada
a day ago
- Cision Canada
The Princess Margaret Cancer Foundation Raises Over $1.16 Million at Inaugural Cricket to Conquer Cancer - Canada's Largest Street Cricket Fundraiser
Hundreds united to support life-saving cancer research and create a world free from the fear of cancer MISSISSAUGA, ON, May 31, 2025 /CNW/ - More than 400 cricketers gathered at Celebration Square as The Princess Margaret Cancer Foundation (The PMCF), presented by TD, hosted the inaugural Cricket to Conquer Cancer — the largest street cricket fundraiser in Canada. This landmark event signalled a major moment in Canada's evolving sports landscape and serves as a powerful symbol of community, culture, and hope. "This event is about rallying a community, celebrating diversity, and changing the way cancer is understood, prevented, diagnosed and treated," said Dr. Miyo Yamashita, President and CEO, The Princess Margaret Cancer Foundation. "We are grateful to all the participants and supporters who took to the pitch today to raise funds that will improve cancer outcomes and provide brighter tomorrows for patients here in Canada and around the globe." This exciting first-of-its-kind fundraising event united cancer survivors, caregivers, athletes, celebrities and supporters of all backgrounds in one shared mission: to create a world free from the fear of cancer. "I felt powerless when my mom was diagnosed with breast cancer and when my close friend, Kenroy, passed away from this disease," said Carlos Brathwaite, international cricket star. "I'm proud to bring my passion for cricket to Canada to help launch this event and raise funds for cancer research that can help transform cancer care and treatment everywhere– including my home, Barbados." With 2 in 5 Canadians facing a cancer diagnosis in their lifetime, the event was more than just a game—it was a community movement for collective impact. Proceeds will benefit life-saving research at Princess Margaret Cancer Centre, one of the world's leading cancer research and treatment centres. Top fundraising teams had the unique opportunity to draft celebrity players onto their teams through a celebrity draft including notable ambassadors Jully Black, Jamaal Magloire, Dwayne De Rosario and Carlos Brathwaite. These household names joined local teams on the pitch, highlighting the inclusive and celebratory nature of the event. "As a daughter of Jamaican immigrants, cricket was a source of endless joy in my family," said Jully Black, Canadian singer-songwriter and artist. "This cause is deeply personal. Cancer has touched every corner of my life—my father is a proud survivor, sadly my mother and grandmother passed away from the disease, and at 27 years old, I too, faced my own cancer scare. These experiences left a profound impact on me. I jumped at the opportunity to champion a cause that uplifts, educates, and unites communities to bring hope in the face of a cancer diagnosis." Cricket to Conquer Cancer's event included a full day of family-friendly festivities with cricket matches, live musical performances, food trucks, cultural cuisine, and interactive cricket experiences for all ages. While this year's fundraiser has come to a close, The Princess Margaret encourages new and returning participants to register online for next year's Cricket to Conquer Cancer event at ABOUT PRINCESS MARGARET CANCER FOUNDATION The Princess Margaret Cancer Foundation is Canada's largest cancer charity. We're dedicated to raising funds for Princess Margaret Cancer Centre, one of the world's leading cancer research and treatment centres, known for its breakthrough discoveries that transform patient outcomes. Together, our work benefits cancer patients everywhere in our mission to create a world free from the fear of cancer. Through philanthropy, fundraising events, and our world-leading lottery program, we're changing how the world understands, prevents, diagnoses, and treats cancer, benefitting patients at The Princess Margaret, throughout Canada, and around the world.
